Key result
Managing HIV- and ART-induced dyslipidemia requires tailored risk assessment and navigating drug-drug interactions.
This review emphasizes the critical need for early and aggressive assessment and treatment of dyslipidemia in people living with HIV, taking into account the pathophysiology of HIV and antiretroviral therapy-induced dyslipidemia as well as drug-drug interactions.
The advent of newer and better tolerated antiretroviral therapy has progressively shortened the life expectancy gap between people living with HIV (PWH) and the general population. However, in this aging cohort, cardiovascular disease is now a significant cause of morbidity and mortality despite advances in cardiac care. Therefore, it is critical to assess and treat all cardiovascular disease risk factors, including dyslipidemia, early and aggressively in PWH. Data are not as robust regarding the pathogenesis and management of dyslipidemia in PWH, with most evidence being extrapolated from the general uninfected population. In this review the authors describe the current understanding of the pathophysiology of HIV and antiretroviral therapy-induced dyslipidemia, and the approach to risk assessment and management, given that drug-drug interactions remain an important consideration in this population.
No takes yet. Share an insight, caveat, or question.
Kalra et al. (2023) conducted a review in HIV and antiretroviral therapy-induced dyslipidemia. Antiretroviral therapy-induced dyslipidemia was evaluated. This review describes the pathophysiology, risk assessment, and management of HIV and antiretroviral therapy-induced dyslipidemia, emphasizing the importance of managing drug-drug interactions.
Synapse has enriched 5 related papers. Consider them for comparative context: